London, United Kingdom – January 08, 2026 – (SeaPRwire) – Capital Margin Trade has announced a continued focus on strengthening its trading tools, placing practicality ahead of feature volume. The initiative reflects a broader effort to refine how traders interact with the platform on a daily basis, particularly in environments where clarity, timing, and execution discipline tend to outweigh visual appeal or experimental features. The Capital Margin Trade trading platform is built around a straightforward premise. Trading tools should work together smoothly and remain accessible under real market conditions. Market access, charting, and order management are combined within a single interface, reducing the need to switch between sections during active trading. Over time, this type of structure often proves more valuable than frequent interface changes that require constant readjustment. Charting has been one of the more fully formed components of the platform. With multiple chart time frames, layered indicators, and customizable chart layouts, users have an opportunity to evaluate price action without extraneous distractions. The tools continue to remain stable even in times of increased volatility, which is often when stability can become a major issue. While the platform does not aim to replicate institutional-grade software, it offers sufficient analytical depth to support structured technical analysis and routine market monitoring. Execution tools on the Capital Margin Trade broker platform follow a similar logic. Orders can be placed and managed without interrupting the broader workflow, allowing traders to stay focused on market movement rather than interface navigation. Real-time price feeds across supported instruments provide continuous visibility, helping users react as conditions change. Execution speed, as with any platform, remains dependent on market conditions, though overall performance is generally consistent during standard trading hours. Risk management features are integrated directly into the trading process. Users can input a stop-loss and/or take-profit level at the time they enter a trade, or adjust those levels once their trades are active. This provides users with the opportunity to make decisions based upon their own risk assessment without forcing the use of pre-defined automated strategy templates. While some traders may look for deeper automation, others may value the ability to remain closely involved in managing exposure. Beyond execution and charting, the Capital Margin Trade trading platform includes a market overview section that offers context without constant interruptions. Instead of relying on frequent alerts, traders can access summarized information when needed. This quieter approach supports independent analysis and may suit users who prefer to interpret data rather than respond to prompts. Accessibility across devices remains consistent. The Capital Margin Trade broker infrastructure is web-based, allowing traders to access accounts from desktops, laptops, tablets, or smartphones without additional downloads. While mobile trading naturally limits screen space, essential functions such as monitoring positions and placing orders remain available, which can be useful for traders managing positions away from their primary setups. In terms of the way the user interacts with the platform, there are multiple layers of operational complexity. The account settings, margin controls, and view of all open positions are clearly defined and separate from each other, allowing for greater ease of managing exposure to risk without having to navigate through layers of menu options. During active market phases, this clarity can help reduce operational friction. Traders seeking highly customized algorithmic environments may find the setup more manual, though this appears intentional for users who prefer hands-on control. Funding and withdrawal processes follow established industry standards. The platform supports commonly used payment methods and prioritizes reliability over experimentation. While options may seem limited for users seeking alternative payment solutions, transaction procedures remain clear and supported by standard verification processes. Security is treated as a baseline requirement rather than a headline feature. Capital Margin Trade trading platform operations include user verification protocols and encrypted data handling designed to protect account access and transactional information without adding unnecessary complexity to daily use. Overall, the ongoing development of Capital Margin Trade broker services suggests a measured, methodical approach. The emphasis has shifted from seeking rapid expansion and numerous new features every few weeks to maintaining a consistent and reliable trading environment. The steady, long-term nature of this strategy could be attractive to those who have become accustomed to using a platform that they feel comfortable with over time, as opposed to having to adjust to rapidly changing tool behavior and workflow changes at short notice. In addition, for traders who place high value on stability, consistency, and predictability in their trading activities (i.e., those who are able to derive long-term benefits from the familiarity of a consistent trading environment), this long-term approach will likely lead to a more productive long-term trading experience than one based on continuous upgrades. About Capital Margin Trade Capital Margin Trade is an online brokerage firm that provides web-based access to global financial markets, utilizing a web-based trading platform. Capital Margin Trade is focused on providing useful tools to assist traders, along with a stable, functional platform structure that supports traders who take a disciplined, execution-oriented approach to trading versus traders who want to constantly experiment with feature-rich platforms. Media Contact Brand: Capital Margin Trade Contact: Media Relations Team Email: press@capitalmargintrade.com Website: https://capitalmargintrade.com

SINGAPORE, Dec 24, 2025 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced the appointment of Gladys Wang as Vice President, Bioprocessing Commercial for Asia, Middle East and Africa (AMEA). With over twenty years of experience in life sciences and commercial leadership, Gladys will oversee Avantor’s business expansion in the AMEA region, enhance customer success initiatives, and drive the development of strategic partnerships throughout the bioprocessing ecosystem. Gladys, based in Singapore, has extensive experience collaborating with biopharma manufacturers, contract development and manufacturing organizations (CDMOs), and key opinion leaders. She is widely recognized for her expertise in delivering transformative business results through customer-centric strategies, operational excellence, and effective cross-market collaboration. Before joining Avantor, Gladys held senior leadership roles at top life sciences organizations, including Head of Global Strategic Accounts APAC and Senior Director for Bioprocessing South Asia & Oceania. She was instrumental in accelerating Asia-Pacific expansion, delivering material business growth through disciplined market-entry strategy. “The Asia, Middle East and Africa region is full of potential, and being part of a team that partners so closely with customers to advance innovation and strengthen manufacturing capabilities is truly motivating. The focus ahead will be on deepening collaboration, enhancing customer experience, and empowering teams to deliver meaningful impact across the bioprocessing value chain. Contributing to Avantor’s continued growth and supporting customers in reaching their scientific and operational objectives is an exciting prospect,” said Gladys Wang, Vice President, Bioprocessing Commercial, Asia, Middle East & Africa. Gladys holds a Master’s degree in Biology from National Taiwan University and has completed executive programs at INSEAD and Stanford University, specializing in strategic transformation and innovation. With her commitment to excellence and talent for cultivating future leaders, Gladys will further strengthen Avantor’s position as a trusted partner for bioprocessing customers across the AMEA region. About Avantor® Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook. Regional Media Contact: Swati Chhabra Manager - Corporate Communications, AMEA Avantor 91-9958-404-334 Swati.Chhabra@avantorsciences.com Global Media Contact Eric Van Zanten Head - External Communications Avantor 610-529-6219 Eric.Vanzanten@avantorsciences.com

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/